The U.S. Food and Drug Administration granted approval to daraxonrasib, a daily oral medication developed by Revolution Medicines under the brand name Rasonque, for patients with metastatic pancreatic cancer who have previously received chemotherapy.
Clinical Trial Results and Survival Rates
According to clinical trial data, daraxonrasib significantly extended overall survival compared to standard chemotherapy regimens. In the RASoute 302 trial involving approximately 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC), participants receiving daraxonrasib achieved a median overall survival of 13.2 months, compared to 6.7 months for patients receiving standard chemotherapy. Patients taking the drug also experienced a progression-free survival median of 7.2 months, versus 3.6 months for the control group.
“The approval of today brings a new option that is critical for patients facing a cancer historically and extraordinarily difficult to treat,” stated FDA Acting Commissioner Kyle Diamantas.
Anna Berkenblit, chief scientific and medical officer at the Pancreatic Cancer Action Network, described the clinical benefit as unlike anything previously observed in advanced pancreatic malignancies.
Mechanism of Action Against KRAS and RAS Proteins
Daraxonrasib targets mutated variants of the RAS protein family, which drive tumor growth in the majority of pancreatic cancers. For decades, researchers considered KRAS undruggable due to its smooth surface structure lacking traditional pockets for drug molecules to bind. The drug utilizes a molecular glue mechanism to bind and deactivate active RAS proteins, shutting down the signaling pathways that fuel uncontrolled cellular proliferation.
Brian Wolpin, a researcher at the Dana-Farber Cancer Institute who led the primary study, stated that he had not previously witnessed such responses in pancreatic cancer clinical trials. Kevan Shokat, a scientist at the University of California, San Francisco, identified crucial structural vulnerabilities in KRAS in 2013, paving the way for the development of targeted inhibitors.
Regulatory Review and Breakthrough Designations
The FDA completed the regulatory review more than six months ahead of its scheduled action date. The standard 5-year survival rate for patients whose disease has extended to distant organs remains around 3%, underlining the clinical challenge posed by the disease.
